Met Kinase Inhibitor SU11274 (CAS: 658084-23-2) is a small molecule inhibitor of Met kinase, which has shown potential therapeutic benefits in various types of cancers.
Introduction to SU11274 SU11274 is a potent and selective inhibitor of Met kinase, which is a receptor tyrosine kinase that plays a critical role in the regulation of cell growth, survival, migration, and invasion. Met activation is associated with various oncogenic processes, including tumor growth, angiogenesis, and metastasis. Therefore, Met kinase inhibitors have been considered as promising cancer therapeutics.
Chemical Name, Molecular Formula, Formula Weight, and CAS No. The chemical name of SU11274 is N-(4-(1,3-benzodioxol-5-yl)-5-(tert-butyl)-1H-pyrazol-3-yl)-4-(tert-butyl)benzamide. The molecular formula of SU11274 is C19H21N3O3, and its formula weight is 339.39 g/mol. The CAS number of SU11274 is 658084-23-2.
Top 10 Keywords from Google and Synonyms
Synonyms:
Health Benefits of SU11274 Numerous studies have suggested that SU11274 has potential health benefits as an anticancer agent. It targets Met kinase, which is known to be overexpressed or activated in several types of cancers, including lung cancer, breast cancer, ovarian cancer, and gastric cancer. By inhibiting Met kinase, SU11274 interferes with the signaling pathways involved in tumor growth, survival, and progression, and thus may prevent the spread of cancer cells.
Potential Effects of SU11274 Several preclinical and clinical studies have reported the potential effects of SU11274 in cancer therapy. In vitro studies have shown that SU11274 inhibits the proliferation, migration, and invasion of cancer cells, and induces apoptosis or programmed cell death. In vivo studies in animal models have demonstrated that SU11274 suppresses tumor growth and metastasis, and enhances the efficacy of chemotherapy and radiotherapy.
Product Mechanism SU11274 acts by selectively inhibiting the tyrosine kinase activity of Met receptor, which is a transmembrane protein that binds to hepatocyte growth factor (HGF) and activates downstream signaling pathways involved in cell growth, survival, migration, and invasion. SU11274 binds to the ATP-binding site of Met kinase and prevents its autophosphorylation, which leads to the inhibition of downstream signaling cascades, such as PI3K/Akt and MAPK/Erk, involved in cell proliferation, survival, and motility.
Safety of SU11274 Although SU11274 has shown promising results in cancer therapy, it may also have potential safety concerns. The toxicity profile of SU11274 has been evaluated in preclinical studies and clinical trials, and the most common adverse events reported were gastrointestinal disturbances, fatigue, headache, and hematological toxicity. However, the safety and tolerability of SU11274 may vary depending on the patient population, dose, and treatment schedule.
Side Effects of SU11274 The most common side effects of SU11274 reported in clinical trials include nausea, vomiting, diarrhea, fatigue, headache, and myelosuppression. Rare but serious adverse events associated with SU11274 include liver toxicity, pulmonary embolism, and cardiovascular events. Patients receiving SU11274 should be monitored for any signs of adverse effects and treated accordingly.
Dosing Information of SU11274 The dosing regimen of SU11274 may vary depending on the type and stage of cancer, patient characteristics, and treatment goals. The recommended dose of SU11274 in clinical trials ranged from 25 mg to 75 mg per day, administered orally once or twice daily. The duration of treatment may also vary depending on the response and tolerance of the patient.
Conclusion In conclusion, SU11274 is a promising Met kinase inhibitor that has shown potential therapeutic benefits in various types of cancers. It targets the signaling pathways involved in tumor growth, survival, and metastasis, and thus may enhance the efficacy of standard chemotherapy and radiotherapy. However, further studies are needed to determine the optimal dosing regimen, safety profile, and clinical efficacy of SU11274 in cancer therapy
